Cladribine: Adalvo makes good progress on a challenging development

02 June 2022

Our key commitment is to deliver diversified and competitive assets, supporting our partners in every step of their journey. This is what positions Adalvo for success.

We are pleased to announce the successful progression of Cladribine, which is being developed based on the reference brand Mavenclad (Merck) and is indicated in the treatment of Multiple Sclerosis.

The product sold at around $900mio globally in 2021, according to IQVIA with a very intensive 3Y-CAGR of 67%.

Whilst we are aware that this is a challenging development with many barriers for competition, we believe we can be among the first companies to file a generic in EU, and potentially an ANDA in US.

Disclaimer: Cladribine which is subject to patent protection are currently not offered or made available in countries where patents are in force.